Turn Therapeutics (TTRX) Net Equity Issued and Repurchased (2024 - 2025)
Turn Therapeutics (TTRX) posted quarterly Net Equity Issued and Repurchased of $3.2 million for Q4 2025, down 95.76% year-over-year from $75.0 million in Q4 2024, and up 959.23% quarter-over-quarter from $300000.0 in Q1 2025.
Powered by 
Analysis
Turn Therapeutics (TTRX) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Turn Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $3.2 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased fell 95.76% year-over-year to $3.2 million; the TTM figure through Mar 2025 stood at $300000.0 (changed N/A YoY), while the FY2025 annual figure was $6.9 million, up 500.45% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $3.2 million, up from $300000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $75.0 million in Q4 2024, with the low at $300000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Turn Therapeutics | 302.05 Mn | 302.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 3.18 Mn |
| Sep 30, 2025 | 594,617.00 |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 998,092.00 |
| Dec 31, 2024 | 75.00 Mn |